[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Hutchison Pharmaceuticals Limited\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100611510","phase-3-phase-iii-clinical-trial-of-shpl-49-injection-in-the-treatment-of-acute-ischemic-stroke-100611510",false,"NCT07241520","Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke","Phase III Clinical Trial to Evaluate the Efficacy and Safety of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke（SAIL）- a Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial","SAIL","Inclusion Criteria:\n\n1. Age 18-80 years old (including upper and lower limits);\n2. Clinically diagnosed as acute ischemic stroke according to the latest guidelines;\n3. Patients diagnosed as acute ischemic stroke who plan to receive or have received standard intravenous thrombolysis in hospital (this research center) within 8hours of symptom onset;\n4. Patients who have NIHSS score≥5 and ≤ 22 before thrombolysis;\n5. Pre-stroke mRS score ≤1;\n6. Patients or legally authorized representatives who are able and willing to sign informed consent.\n\nExclusion Criteria:\n\n1. Complicated with intracranial hemorrhagic diseases, including hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc.;\n2. Severe disturbance of consciousness: patients with NIHSS 1a consciousness level item score ≥2;\n3. Cerebral Computed tomography (CT) or Magnetic resonance imaging (MRI) indicated a large anterior circulation cerebral infarction (infarct area greater than 1\u002F3 of the middle cerebral artery blood supply area);\n4. Stroke with rapid improvement of symptoms before intravenous thrombolysis, or acute ischemic symptoms suspected to be caused by other causes;\n5. Patients who are ready to receive or have received endovascular therapy;\n6. After the onset of the disease, the drugs with neuroprotective effects which have been used: commercially available Edaravone, Edaravone and Dexborneol, Butylphthalide, Citicoline, Nimodipine, Ganglioside, Human Urinary Kallidinogenase, Cinepazide, Cattle Encephalon Glycoside and Ignotin, Fasudil, Compound Porcine Cerebroside and Ganglioside, Piracetam, Oxiracetam, Mouse Nerve Growth Factor For Injection, Cerebrolysin, Deproteinised Calf Blood Serum Injection, Deproteinised Calf Blood Extractives Injection, Ginkgolides Injection, Ginkgolides Diterpene Lactone Meglumine Injection, Ginkgo Leaf Extract and Dipyridamole Injection, Extract of Ginkgo Biloba Leaves Injection, Safflower Extract and Aceglutamide Injection, Xuesaitong Injection, Xuesaitong Soft Capsules, and injections containing any single eXtract of Chuanxiong (Chuanxiong Rhizoma), Danshen (Salviae Miltiorrhizae Radix ET Rhizoma), Hongjingtian (Rhodiolae Crenulatae Radix Et Rhizoma),or several of these Chinese herbal ingredients;\n7. Patients with a history of atrial fibrillation, deep vein thrombosis of the lower extremities, pulmonary embolism or other conditions that require the use of anticoagulant drugs during administration;\n8. Severe hypertension: systolic blood pressure ≥180mmHg or diastolic blood pressure ≥100mmHg after taking antihypertensive drugs before thrombolysis;\n9. Severe renal insufficiency: serum creatinine \\>2 times upper limit of normal or creatinine clearance (CLcr) \\\u003C 30mL\u002Fmin (Cockcroft-Gault formula), or with other known severe renal insufficiency such as renal failure and uremia ; (Note: Cockcroft Gault formula: (1) Male: CLcr (mL\u002Fmin) = \\[140 - age (yrs)\\]× body weight (kg) \u002F \\[0.814 × serum creatinine (μmol\u002FL)\\]; (2) female: CLcr (mL\u002Fmin) = {\\[140 - age (years old)\\] by weight (kg) \u002F \\[0.814 x serum creatinine (μmol\u002FL)\\]} x 0.85);\n10. Severe hepatic function impairment: Alanine aminotransferase (ALT) or Aspartate aminotransferase(AST) 3 times upper limit of normal, or with other known hepatic diseases such as hepatic failure, hepatic cirrhosis, portal hypertension (with esophageal varices), active hepatitis, etc.;\n11. Patients with a heart function rating above Class II (according to the New York Heart Association (NYHA) heart function rating) or a history of congestive heart failure;\n12. Patients with malignant tumors or undergoing anti-tumor therapy;\n13. Allergic to experimental drugs or similar ingredients or materials used in imaging examinations;\n14. Patients during pregnancy, lactation or planning pregnancy;\n15. Patients who have a history of epilepsy or have had seizure-like symptoms at the onset of stroke, or suffer from serious mental disorders, intellectual disabilities or dementia;\n16. Alcohol dependence, or drinking more than 3 units (male) or 2 units (female) of alcohol within 24 hours prior to onset (1 unit =360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine);\n17. Patients have participated in other drug or non-drug clinical studies, or are participating in another clinical study within 3 months before signing informed consent form;\n18. Patients have a history of severe head trauma or stroke within the past 3 months;\n19. Patients are suffering from severe systemic diseases, with a life expectancy of less than 90 days;\n20. Patients who are judged unsuitable for participation by the investigators in the study.","ALL","18 Years","80 Years",{"count":21,"type":22},1096,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.",[28],"Acute Ischemic Stroke","RECRUITING","2026-01-03",{"date":32,"type":33},"2026-01-06","ACTUAL",{"date":35,"type":33},"2025-12-08",{"date":37,"type":22},"2027-11-30",{"name":39,"class":40},"Shanghai Hutchison Pharmaceuticals Limited","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":41},"100604763","phase-4-efficacy-and-safety-of-shexiang-baoxin-pillmuskardia-in-the-treatment-of-acute-myocardial-infarction-100604763","NCT07153744","Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction","Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction: A Prospective, Multicenter, Pragmatic Randomized Controlled Real-World Study","MUST Ⅱ","Inclusion Criteria:\n\n* Aged 18 years or older, regardless of gender\n* In accordance with the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes , meeting the diagnostic criteria for acute myocardial infarction, including typical chest pain lasting for ≥20 minutes, electrocardiographic manifestations of ST-segment elevation (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), and serum high-sensitivity troponin (hs-cTn) levels exceeding the 99th percentile of the upper reference limit at least once with dynamic changes\n* Presenting for treatment within \\\u003C24 hours of symptom onset and scheduled to undergo PCI\n* The patient or their guardian has signed the informed consent form\n\nExclusion Criteria:\n\n* Having contraindications to PCI treatment\n* Being allergic to Shexiang Baoxin Pills, unable to tolerate them, or having other conditions that prevent completion of the trial drug administration\n* Being pregnant, planning to become pregnant, or breastfeeding women\n* Having participated in other clinical studies within 3 months\n* Being deemed unsuitable for inclusion in this study by the researcher",{"count":51,"type":22},9588,[53],"PHASE4","This study aims to evaluate the value of Shexiang Baoxin Pill (MUSKARDIA) in patients with acute myocardial infarction (AMI) through a prospective, multicenter, pragmatic randomized controlled real-world study. It seeks to validate its efficacy in reducing cardiovascular event risk during the peri-PCI period, as well as its effects on cardiac function, quality of life , and relevant biomarkers. Through this research, we expect to provide higher-quality evidence for the application of SBP in AMI patients undergoing PCI, thereby further optimizing comprehensive treatment strategies for AMI.",[56,57],"Acute Myocardial Infarction (AMI)","Percutaneous Coronary Intervention (PCI)",[59,60,61,62,63,64,65,66],"Acute Myocardial Infarction","AMI","Percutaneous Coronary Intervention","PCI","Shexiang Baoxin Pill","MUSKARDIA","Shexiang Baoxin Pill(MUSKARDIA)","SBP","NOT_YET_RECRUITING","2025-08-26",{"date":70,"type":33},"2025-09-04",{"date":72,"type":22},"2025-09-01",{"date":74,"type":22},"2029-12-31",{"name":39,"class":40},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":96,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":41},"100574160","a-prospective-multicentre-real-world-assessment-of-the-efficacy-of-danning-tablets-in-alleviating-digestive-symptoms-100574160","NCT06755671","A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms","Inclusion Criteria:\n\n* Patients between 18 and 75 years old\n* Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation\n* Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia\n* Patients agree to sign the informed consent form\n\nExclusion Criteria:\n\n* Past history or comorbidity of malignant tumor\n* Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases\n* Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden)\n* Comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician\n* Pregnancy or breastfeeding\n* Participation in other clinical trials within the past 3 months\n* Other circumstances determined as ineligible by the research physician","75 Years",{"count":84,"type":22},4500,"OBSERVATIONAL","The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation.\n\nThe main questions it aims to answer are:\n\nHow effective are Danning Tablets for patients with indigestion symptoms? What are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of Danning Tablets for indigestion patients?\n\nParticipants already taking Danning Tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.",[88,89,90,91,92,93,94,95],"Indigestion","Dyspepsia","Bloating","Loss of Appetite","Reflux Acid","Constipation","Upper Abdominal Pain","Functional Dyspepsia",[97,98,99,100,101],"Danning Tablets","dyspepsia","indigestion","observational study","real world study","2025-05-13",{"date":104,"type":33},"2025-05-14",{"date":106,"type":33},"2025-04-30",{"date":108,"type":22},"2027-06-30",{"name":39,"class":40},""]